Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Allergy, Peanut

In brief

This was a 52-week, Phase 3 multi-center, randomized, double-blind and placebo-controlled study to assess the safety and clinical efficacy of two dosing regimens of ligelizumab (240 mg and 120 mg) SC q4w (subcutaneous injection every 4 weeks) in participants with a medically confirmed diagnosis of Immunoglobulin E (IgE) mediated peanut allergy.

Key facts

Study ID
NCT04984876
Run by
Novartis Pharmaceuticals
People needed
211
Starts
2021-12-07
Expected to finish
2023-11-27
Last updated by the study team
2025-04-29

Who can join

Age: 6 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.